Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 18/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.36 |
| ▸ | YAP1 | P46937 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098651 | 0.90 | MEN1 (0.42) | ITGA4ITGB1ITGB3ITGAVITGA5 | |
| SCHEMBL7098581 | 0.89 | ITGA4 (0.50) | ITGA4ITGB1YAP1 | |
| SCHEMBL7098578 | 0.89 | ITGA4 (0.50) | ITGA4ITGB1YAP1 | |
| SCHEMBL7105344 | 0.84 | ITGA4 (0.47) | ITGA4ITGB1ITGB3ITGAVITGA5 | |
| SCHEMBL7101431 | 0.83 | ITGA4 (0.58) | ITGA4ITGB1 | |
| SCHEMBL7101426 | 0.83 | ITGA4 (0.58) | ITGA4ITGB1 | |
| SCHEMBL7520798 | 0.83 | ITGA4 (0.58) | ITGA4ITGB1 | |
| SCHEMBL7102829 | 0.82 | ITGA4 (0.51) | ITGA4ITGB1 | |
| SCHEMBL7102826 | 0.82 | ITGA4 (0.51) | ITGA4ITGB1 | |
| SCHEMBL6561191 | 0.81 | ITGB1 (0.43) | ITGA4ITGB1ITGB3ITGAVITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6596752-B1 | Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | ITGA4 8/4885ITGB1 3/4885ITGB3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.